Search research articles
Contact Us
Filters
Showing results (71-80 of 129) with videos related to
Page
of 13
Sort By:
Oncology Reports
|
May 23, 2012
Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07
Peter Schraml, Adriana von Teichman, Daniela Mihic-Probst, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
February 10, 2009
Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?
Karin Ribi, Dieter Koeberle, Jan C Schuller, et al.
Cancer Immunology, Immunotherapy : CII
|
April 14, 2006
Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma
Ying Waeckerle-Men, Edith Uetz-von Allmen, Markus Fopp, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 16, 2011
Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO
Xavier Pivot, Andreas Schneeweiss, Shailendra Verma, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 12, 2008
Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts
Roger von Moos, Beat J K Thuerlimann, Matti Aapro, et al.
Journal of Geriatric Oncology
|
September 30, 2023
Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer: An analysis of the prospective QoLiTrap study
Gudrun Piringer, Josef Thaler, Sandro Anchisi, et al.
Endocrine Oncology (Bristol, England)
|
July 12, 2023
SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients
Marcus Vetter, Karin M Rothgiesser, Qiyu Li, et al.
Wiener Klinische Wochenschrift
|
July 9, 2013
Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease
Rodica Anghel, Alexander Bachmann, Meral Bekşac, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
October 29, 2013
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors
David Henry, Saroj Vadhan-Raj, Vera Hirsh, et al.
Onkologie
|
May 27, 2010
Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02)
Thomas Ruhstaller, Arnoud Templeton, Karin Ribi, et al.
Page
of 13
Search research articles
Search
Showing results (71-80 of 129) with videos related to
Sort By:
Page
of 13
Oncology Reports
|
May 23, 2012
Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07
Peter Schraml, Adriana von Teichman, Daniela Mihic-Probst, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
February 10, 2009
Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?
Karin Ribi, Dieter Koeberle, Jan C Schuller, et al.
Cancer Immunology, Immunotherapy : CII
|
April 14, 2006
Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma
Ying Waeckerle-Men, Edith Uetz-von Allmen, Markus Fopp, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 16, 2011
Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO
Xavier Pivot, Andreas Schneeweiss, Shailendra Verma, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 12, 2008
Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts
Roger von Moos, Beat J K Thuerlimann, Matti Aapro, et al.
Journal of Geriatric Oncology
|
September 30, 2023
Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer: An analysis of the prospective QoLiTrap study
Gudrun Piringer, Josef Thaler, Sandro Anchisi, et al.
Endocrine Oncology (Bristol, England)
|
July 12, 2023
SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients
Marcus Vetter, Karin M Rothgiesser, Qiyu Li, et al.
Wiener Klinische Wochenschrift
|
July 9, 2013
Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease
Rodica Anghel, Alexander Bachmann, Meral Bekşac, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
October 29, 2013
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors
David Henry, Saroj Vadhan-Raj, Vera Hirsh, et al.
Onkologie
|
May 27, 2010
Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02)
Thomas Ruhstaller, Arnoud Templeton, Karin Ribi, et al.
Page
of 13